Ardent Health Corporation Securities Fraud Class Action Result of Undisclosed Collections Problems and 33% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
ARDT sits 17% above its 52-week low of $8.07.
Summary
Kahn Swick & Foti, LLC has announced a securities fraud class action lawsuit against Ardent Health Corporation, with a lead plaintiff deadline of March 9, 2026. The lawsuit alleges the company failed to disclose material information to investors between July 2024 and November 2025. Specifically, the action cites Ardent's November 2025 disclosure of a $43 million decrease in Q3 2025 revenue due to revised accounts receivable collectability and a $57.5 million reduction in 2025 EBITDA guidance, alongside a $54 million increase in professional liability reserves. These revelations caused the stock to drop nearly 34%. This class action poses a significant legal and financial risk for Ardent Health, potentially resulting in substantial settlement costs, ongoing legal expenses, and reputational damage. Investors will be watching for further developments in the litigation and any potential impact on the company's financial outlook.
At the time of this announcement, ARDT was trading at $9.48 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $8.07 to $15.59. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Acceswire.